Colon Cancer: Receptors, Signalling and Therapeutics

结肠癌：受体、信号传导和治疗

• 批准号: nhmrc : 280912
• 负责人: Dr Thomas Garrett
• 金额: $ 474.46万
• 依托单位国家: 澳大利亚
• 项目类别: Programs
• 财政年份: 2004
• 资助国家: 澳大利亚
• 起止时间: 2004-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/colon-cancer-receptors-signalling-therapeutics/80989
• 关键词: Colon; Cancer; Receptors; Signalling; Therapeutics

This program aims to understand the biochemical and biological basis of colorectal cancer, a major cause of cancer deaths in Australia. The Chief Investigators have extensive experience in the analysis of the molecular defects in colorectal cancer cells and have already developed new drugs to treat successfully experimental colon tumours in animals. During this research program, we will explore these systems further, concentrating on the identification of novel inhibitors of colon cancer cell growth, survival and movement. Newly developed instruments and techniques will allow us to identify and detect the critical steps during the development of colorectal cancer and to design potent drugs to fight the disease. We have experience in conducting novel clinical trials in colon cancer and have developed imaging techniques for monitoring the effectiveness and safety of new anti-cancer drugs. Our collective scientific experience and ability to work in the clinic provides a unique opportunity for developing more effective treatments for colorectal cancer patients.

该计划旨在了解结直肠癌的生化和生物学基础，结直肠癌是澳大利亚癌症死亡的主要原因。首席研究员在分析结直肠癌细胞的分子缺陷方面拥有丰富的经验，并已开发出成功治疗动物实验性结肠肿瘤的新药。在本研究计划中，我们将进一步探索这些系统，重点是鉴定结肠癌细胞生长、存活和运动的新型抑制剂。新开发的仪器和技术将使我们能够识别和检测结直肠癌发展过程中的关键步骤，并设计有效的药物来对抗这种疾病。我们在开展结肠癌新型临床试验方面拥有丰富的经验，并开发了用于监测新型抗癌药物有效性和安全性的成像技术。我们集体的科学经验和临床工作能力为开发结直肠癌患者更有效的治疗方法提供了独特的机会。